Retatrutide (LY3437943) is an investigational once-weekly injection being studied for obesity and related conditions. It is not FDA-approved in the US and should only be used in clinical trials. Early Phase 2 data showed large average weight loss, and Phase 3 TRIUMPH studies are designed to confirm benefits and safety in larger, higher-risk populations and outcomes-focused settings.
Retatrutide (LY3437943) is an investigational once-weekly injectable medicine being studied for obesity and metabolic diseases. Because it…
A practical, non-prescriptive guide to managing common retatrutide-related GI side effects—nausea, constipation, and diarrhea—plus red flags and when to contact your clinician.
Short answer (plain English) Retatrutide is investigational and in phase 2 obesity data it caused dose-dependent increases…
How weight loss can affect obstructive sleep apnea (OSA), what AHI means, where retatrutide fits (TRIUMPH trials), and what to ask your clinician about CPAP, testing, and treatment.
Short answer Retatrutide (LY3437943) is a once-weekly triple incretin/glucagon receptor agonist (GIP + GLP‑1 + glucagon) being…
Short answer (for fast readers) Retatrutide is an investigational once-weekly injectable “triple agonist” (GLP-1 + GIP +…
Retatrutide (LY3437943) is an investigational medicine studied for obesity and metabolic disease that activates three hormone receptors—GIP, GLP-1, and glucagon. Together, these signals can reduce appetite, improve blood-sugar control, and may increase energy expenditure, which helps explain the large weight-loss results seen in phase 2 trials.
Short answer The TRIUMPH program is Eli Lilly’s Phase 3 set of studies designed to show whether…
As of 2026-02-02, retatrutide (LY3437943) is not FDA-approved in the United States. The program is in Phase 3 (TRIUMPH), with multiple trials expected to read out and complete on different schedules. The earliest realistic approval timing depends on when Lilly submits an NDA and the FDA sets a PDUFA goal date—neither of which is publicly posted until an application is filed and accepted.